SCHEMBL856474

SCHEMBL856474

CC(C)(O)CCBr

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1247300 0.97
SCHEMBL1184710 0.80
SCHEMBL1459586 0.78
SCHEMBL37987 0.76 ALDH1A1 (1.00)
SCHEMBL5351781 0.76 ALDH1A1 (0.47)
SCHEMBL4898326 0.76 ALDH1A1 (0.47)
SCHEMBL12515765 0.76 ALDH1A1 (0.40)
SCHEMBL12323560 0.74 ALDH1A1 (0.39)
SCHEMBL949685 0.72
Ammonia Solution, Strong SCHEMBL28802926 0.72 ALDH1A1 (0.91)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112409131-A Synthetic preparation method of 3-bromo-2, 2-dimethyl-1-propanol 南京麦瑞米生物技术有限公司 2021-02-26 CN claimed
WO-2017207385-A1 SUBSTITUTED 3-METHYLINDAZOLES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING SAME, AND USE THEREOF FOR THE PRODUCTION OF MEDICAMENTS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-12-07 WO claimed
EP-4743078-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-20 EP disclosed
EP-4737451-A1 NOVEL CARBOXAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Dong Wha Pharm. Co., Ltd. (KR) 2026-05-06 EP disclosed
US-12617802-B2 Sulfonimidamide compounds as NLRP3 modulators GENENTECH, INC. (US) 2026-05-05 US disclosed
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS INC (US) 2026-04-30 US disclosed
EP-4200015-B1 SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL MYERS SQUIBB CO (US) 2026-04-29 EP disclosed
EP-4717695-A1 CRYSTAL FORM AND SALT FORM OF FIVE- AND SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE Hangzhou Polymed Biopharmaceuticals, Inc. (CN) 2026-04-01 EP disclosed
US-20260085057-A1 SUBSTITUTED INDAZOLES USEFUL FOR TREATMENT AND PREVENTION OF ALLERGIC AND/OR INFLAMMATORY DISEASES IN ANIMALS Bayer Pharma AG (DE) 2026-03-26 US disclosed
EP-4714952-A1 COMPOUND AND USE THEREOF Autobio Group Co., Ltd. (CN) 2026-03-25 EP disclosed
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2026-03-10 US disclosed
US-5145846-A Skin disorders, leukemia, sebaceous gland disorders HOFFMANN-LA ROCHE INC. (US) 1992-09-08 US disclosed
EP-0479871-A1 NOVEL VITAMIN D ANALOGUES. LEO PHARM PROD LTD (DK) 1992-04-15 EP disclosed
EP-0325279-B1 DEHYDROCHOLECALCIFEROL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1992-04-01 EP disclosed
US-5087619-A For treatment of skin or gland disorders; antitumor agents HOFFMAN-LA ROCHE INC. (US) 1992-02-11 US disclosed
WO-1991000271-A1 NOVEL VITAMIN D ANALOGUES Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) 1991-01-10 WO disclosed
EP-0325279-A1 Dehydrocholecalciferol derivatives F. HOFFMANN-LA ROCHE AG (CH) 1989-07-26 EP disclosed
US-4772433-A Vitamin D analogues RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY INC. (US) 1988-09-20 US disclosed
EP-0078704-B1 INTERMEDIATES IN THE SYNTHESIS OF VITAMIN D DERIVATIVES RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY INC. (US) 1987-04-29 EP disclosed
EP-0078704-A1 Intermediates in the synthesis of vitamin D derivatives RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY INC. (US) 1983-05-11 EP disclosed